Clinical trials: Clinical Research
Healthy
Randomized, Controlled Study to Compare Straumann® VivOss™ to Geistlich Bio-Oss® in Sinus Floor Augmentation.
A randomized controlled clinical trial to investigate the capability of Straumann® VivOss™ compared to Geistlich Bio-Oss in sinus floor augmentation to demonstrate superiority of Straumann® VivOss™ compared to Geistlich Bio-Oss…
- Trial name
- NCT02288182
- Testing
- Straumann VivOss, Geistlich Bio-Oss
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Institut Straumann AG
Follicular Lymphoma
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
A study to evaluate the safety and efficacy of duvelisib administered in combination with rituximab vs placebo in combination with rituximab in patients with previously treated CD20-positive follicular lymphoma who are not…
- Trial name
- DYNAMO + R (NCT02204982)
- Testing
- Duvelisib, Rituximab
- Where
- 5 sites in Australia, France and 2 more
- Volunteers
- 13 people
- Sponsor
- SecuraBio
Enthesitis Related Arthritis (ERA)
A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis
The purpose of this study is to evaluate the efficacy and safety of adalimumab given subcutaneously every other week (eow) as compared to placebo in pediatric subjects with Enthesitis Related Arthritis (ERA).
- Trial name
- NCT01166282
- Testing
- adalimumab
- Volunteers
- 46 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hereditary Angioedema Types I and II
A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route
The aim of the study is to assess what happens to C1-esterase inhibitor that is administered under the skin of subjects with hereditary angioedema. Three different dosing regimens of C1-esterase inhibitor will be assessed.
- Trial name
- NCT01576523
- Testing
- C1-esterase inhibitor - single intravenous dose, C1-esterase inhibitor - subcutaneous low dose, C1-esterase inhibitor - subcutaneous medium dose
- Where
- 8 sites in United States, Germany
- Volunteers
- 18 people
- Sponsor
- CSL Behring
Depression, Anxiety
Self-Defense Training in Women With Trauma
Previous research has shown that self-defense training can lead to gains in women's assertiveness, self-esteem, self-efficacy, and physical competence, and decreases in anxiety, helplessness, fear, and avoidant behaviors.
- Conditions
- Depression, Anxiety, Stress Disorders, Post-Traumatic
- Trial name
- NCT01380379
- Testing
- Life skills and self-defense training
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Stanford University
Colon Cancer, Colorectal Cancer
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
The primary objective of this study is to estimate the treatment effect on progression-free survival (PFS) of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in patients with…
- Conditions
- Colon Cancer, Colorectal Cancer, Rectal Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT00819780
- Testing
- Panitumumab, Bevacizumab, mFOLFOX6
- Where
- 95 sites in United States, Belgium and 4 more
- Volunteers
- 285 people
- Sponsor
- Amgen
Diabetes Mellitus, Type 1
A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus
The purpose of this research study is to look at concentrations of GSK189075 in blood when single doses of the drug are taken by mouth in combination with basal insulin.
- Trial name
- NCT00575159
- Testing
- GSK189075
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes
The purpose of this study is to evaluate the glucodynamic effects of dulaglutide in Japanese participants with type 2 diabetes mellitus.
- Trial name
- NCT03315780
- Testing
- Dulaglutide
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
Phase 1, TAK-648, Single-Rising Dose Study
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of TAK-648 when administered as a single oral dose of TAK-648 solution at escalating dose levels in healthy participants.
- Trial name
- NCT02684396
- Testing
- TAK-648
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants
The primary objective of this study is to investigate the safety and tolerability of BGB-DXP604 alone and in combination with BGB-DXP593 in healthy participants
- Trial name
- NCT04669262
- Testing
- BGB-DXP604, BGB-DXP593
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- BeiGene
Perennial Allergic Rhinitis
A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis
The purpose of this study is to compare the effectiveness of an Investigational use of an allergy medication (MP03-33) used to treat perennial allergic rhinitis (PAR) to placebo (a nasal spray that contains no medicine).
- Trial name
- NCT01018862
- Testing
- Azelastine hydrochloride nasal spray 0.15%, Azelastine hydrochloride nasal spray 0.10%
- Where
- 39 sites in United States
- Volunteers
- 489 people
- Sponsor
- Meda Pharmaceuticals
Hypertension
Add-on to Micamlo BP Trial
This is a multi-centre, randomised, double-blind, active-controlled, parallel-group comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg +hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5…
- Trial name
- NCT01975246
- Testing
- Telmisartan + amlodipine, hydrochlorothiazide
- Where
- 30 sites in Japan
- Volunteers
- 309 people
- Sponsor
- Boehringer Ingelheim
Distal Tibia Fractures
Zimmer® MotionLoc® in Distal Tibia Fractures
The objective of this observational prospective study is to systematically document the clinical outcomes of Zimmer MotionLoc Screws for Periarticular Locking Plate System applied to distal tibia fracture treatment and confirm…
- Trial name
- NCT02717546
- Testing
- Zimmer MotionLoc Screw
- Where
- 7 sites in United States, Australia and 3 more
- Volunteers
- 32 people
- Sponsor
- Zimmer Biomet
Urinary Tract Infection Complicated, Acute Pyelonephritis
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae
- Conditions
- Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia
- Trial name
- NCT02168946
- Testing
- Vabomere, Best Available Therapy
- Where
- 50 sites in United States, Argentina and 6 more
- Volunteers
- 77 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Bariatric Surgery Candidate, Hiatal Hernia
Safety and Feasibility of Liver Retraction With the Levita Magnetic Surgical System: Extended Magnetic Grasper Device
The purpose of this study is to evaluate the safety and effectiveness of the Extended Magnetic Grasper Device in patients undergoing bariatric and/or hiatal hernia procedures, as a liver retractor grasping the liver and/or the…
- Trial name
- NCT06432088
- Testing
- Extended Magnetic Grasper Device
- Where
- Chile
- Volunteers
- 30 people
- Sponsor
- Levita Magnetics
Schizophrenia
Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)
This 3-part dose titration study will assess elpipodect safety, tolerability, pharmacokinetics (PK), and central nervous system activity.
- Trial name
- NCT02181803
- Testing
- Elpipodect, Base Monotherapy
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Angioplasty, Chronic Coronary Occlusion
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to: Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort…
- Conditions
- Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease
- Trial name
- XV CHINA SAS (NCT01249027)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
- Where
- United States
- Volunteers
- 2,605 people
- Sponsor
- Abbott Medical Devices
Schizophrenia
Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants
The purpose of this study is to evaluate the effectiveness and safety of paliperidone extended release (ER) treatment in Thai schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality…
- Trial name
- PRESENT (NCT01387542)
- Testing
- Paliperidone extended release (ER)
- Where
- 2 sites in Thailand
- Volunteers
- 40 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma
Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer
This phase II trial studies the effect of futibatinib and pembrolizumab in treating patients with FGF19 positive BCLC stage A, B, or C liver cancer that has spread to other parts of the body (advanced or metastatic).
- Conditions
- Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
- Trial name
- NCT04828486
- Testing
- Futibatinib, Pembrolizumab, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Mayo Clinic
PTSD
Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder
This study, conducted at the NIH and the Mount Sinai School of Medicine, will examine the effectiveness of a substance P or NK1 antagonist study drug known as GR205171 in treating the symptoms of posttraumatic stress disorder…
- Trial name
- NCT00383786
- Testing
- NK1 Antagoist (GR205171), Psychophysiology (Trauma Script), Psychophysiology (Verbal Threat)
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Baylor College of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.